Iovance Biotherapeutics Inc is a biotechnology company that focuses on the development and commercialization of cell-based cancer immunotherapies. The company's values revolve around innovation, scientific excellence, and patient-centricity. Iovance Biotherapeutics Inc is committed to pushing boundaries and delivering next-generation therapies to improve patient outcomes. Their corporate philosophy centers on collaboration, transparency, and a passion to make a meaningful impact in the field of oncology. By leveraging their expertise in cellular therapy, Iovance Biotherapeutics Inc aims to address the unmet needs of cancer patients and redefine the treatment landscape.

Iovance Biotherapeutics Inc is primarily present in the United States.

Iovance Biotherapeutics Inc, a leading biotechnology company, has achieved several significant milestones. The company successfully completed the pivotal Study LN-144-01 phase 2 clinical trial, demonstrating the efficacy and safety of its tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma patients. Moreover, Iovance obtained Breakthrough Therapy designation from the FDA for LN-145, its TIL therapy for advanced cervical cancer. The company also secured an exclusive license agreement with the National Cancer Institute, reinforcing its innovative research approach. These milestones underscore Iovance Biotherapeutics' commitment to developing groundbreaking immunotherapies and its potential for transforming the treatment landscape for various cancers.

Iovance Biotherapeutics Inc is a biotechnology company specializing in the development of novel cancer immunotherapies. Founded in 2007, the company is at the forefront of harnessing the power of Tumor-Infiltrating Lymphocytes (TILs) to fight various types of cancer. With its innovative cell therapy platform, Iovance aims to address the unmet medical needs of patients and revolutionize cancer treatment. The company has made significant advancements in clinical trials, demonstrating the potential efficacy of TILs in treating advanced melanoma and cervical cancer. Iovance's commitment to improving patient outcomes and its groundbreaking research has positioned it as a prominent player in the rapidly evolving field of immuno-oncology.

The main competitors of Iovance Biotherapeutics Inc in the market include companies like Adaptimmune Therapeutics plc, Kite Pharma Inc, and Novartis AG.

Iovance Biotherapeutics Inc is primarily active in the biotechnology industry.

Iovance Biotherapeutics Inc, a biotechnology company, focuses on the development and commercialization of autologous cell therapies for the treatment of cancer. By utilizing its proprietary tumor-infiltrating lymphocytes (TIL) technology, Iovance seeks to harness the power of the patient's immune system to target and destroy cancer cells. TIL therapy involves extracting immune cells from the patient's tumor, expanding and activating them in the lab, and then reinfusing them back into the patient. This personalized approach holds the potential to revolutionize cancer treatment by offering a highly specific and targeted therapy. Iovance Biotherapeutics Inc aims to improve patient outcomes and transform the field of oncology through innovative cell therapies.

Poměr Iovance Biotherapeutics P/E je -4,39.

Koeficient Iovance Biotherapeutics tržních hodnot je 10,44.

AlleAktien kvalitní skóre pro Iovance Biotherapeutics je 5/10.

očekávané Iovance Biotherapeutics obrat je 164,41 mil. USD.

očekávané Iovance Biotherapeutics zisk je -390,75 mil. USD.

Iovance Biotherapeutics Inc. specializes in the development and production of innovative cell therapies that can improve the lives of patients with hard-to-treat cancers. The company has two main products in their pipeline - LN-144 and LN-145, which are based on Iovance's proprietary technology platform. The company's cell therapies are based on extracting tumor cells from the patient, which are then cultured and genetically manipulated in the lab. Through this manipulation, these cells can activate the patient's own immune system to attack and destroy cancer cells. The cells are then reintroduced into the patient to allow for targeted and personalized treatment. Iovance Biotherapeutics' core business is to achieve regulatory approval and commercialize these innovative cell therapies, maximizing their global distribution. The company aims to rely on IT support and data analysis to build extensive databases of patient outcomes and gain long-term scientific insights from the treatment with their cell therapies. The company has obtained approval in the US and EU to conduct clinical studies with LN-145, a cell-based therapy for the treatment of recurrent or metastatic cervical cancer. Studies with these therapies have shown successful results in up to 44 percent of patients with advanced disease. The company also aims to rapidly develop and market LN-144 as a cellular therapy for the treatment of melanoma and other solid tumors. Furthermore, the company is also pursuing other initiatives to expand its product offering and global reach. Iovance plans to collaborate with researchers, physicians, and academic institutions to expand its own technology and expertise, thus improving the production and use of CAR-T cells and other cell-based therapies. Iovance Biotherapeutics' business model is tailored to the needs of affected patients searching for new treatment options to fight their cancers. The company relies on its extensive experience in cell therapy manufacturing and its close relationships with the medical community to market and distribute its products globally. Iovance aims to remain a leader in cancer therapy in the long term by expanding its technology and expertise, thereby staying at the forefront of medical research and innovation.

Iovance Biotherapeutics vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro Iovance Biotherapeutics momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Iovance Biotherapeutics je US4622601007.

WKN společnosti Iovance Biotherapeutics je A2DT49.

Ticker společnosti Iovance Biotherapeutics je IOVA.

Během posledních 12 měsíců vyplatila společnost Iovance Biotherapeutics dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Iovance Biotherapeutics vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti Iovance Biotherapeutics aktuálně činí .

Iovance Biotherapeutics vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Iovance Biotherapeutics vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

Iovance Biotherapeutics je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Iovance Biotherapeutics ve výši 0 USD, zaznamenané 11. 7. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 11. 7. 2024.

Poslední dividendy byly vyplaceny dne 11. 7. 2024.

V roce 2023 společností Iovance Biotherapeutics bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti Iovance Biotherapeutics jsou vypláceny v USD.